Key Points:

• 101 consecutive MDS samples were evaluated with traditional cytogenetic methods (karyotyping, FISH, CMA), an 81-gene NGS panel, and OGM
• OGM found nearly double the number of clinically relevant pathogenic variants compared to traditional cytogenetics
• OGM findings could inform different prognostic risk classification or identify important additional variants in 28% of study participants
• Changes to CCSS and IPSS-R risk scores in 21% and 17% of subjects, respectively.
• Additional 13% of samples had additional alternations researchers suggest could be used for therapy selection/response and disease monitoring
• The combination of OGM and NGS resulted in the detection of at least one clinically significant clonal abnormality in 97 of 101 samples